Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne ...

FDA 510(k) clearance of Caristo's CaRi-Plaquetm technology advances AI innovator's U.S. commercialization, as it looks to roll out to hospitals, health systems and longevity clinicsThe CaRi-Plaque ...

March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or ... is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for ...

On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s CAPR Biologics ... DMD cardiomyopathy is a heart condition characterized by cardiac fibrosis, arrhythmias, and heart failure.

and heart failure. Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 31, 2025. The FDA has not identified any potential ...

--(BUSINESS WIRE)--Cadrenal Therapeutics ... heart pumps have set the standard in LVAD therapy. The HeartMate 3™ LVAD is the most advanced LVAD yet and the only one currently available in the ...

LGT Fund Management Co Ltd. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $ ...

United Therapeutics stock opened at $319.96 on Thursday. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The company has a market capitalization of $14.28 billion ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...

United Therapeutics Corporation beats earnings expectations ... And at the International Society for Heart and Lung Transplantation Conference in Boston on April twenty-seventh to the thirtieth.

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...